Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.

作者: Volker Kunzmann , Thomas Ruediger , Michael Hallek , Hans-Konrad Mueller-Hermelink , Martin Wilhelm

DOI: 10.1182/BLOOD.V98.6.1991

关键词:

摘要: The chimeric monoclonal anti-CD20 antibody has been widely used for the treatment of relapsed or refractory low-grade B-cell non-Hodgkin lymphoma (NHL). However, in patients with a high number tumor cells blood, severe infusion-related toxicities have reported.[1][1] On basis

参考文章(5)
P. C. W. Hogendoorn, P. M. Kluin, M. R. Daha, M. A. Van Buchem, R. Willemze, C. N. Levelt, L. P. Colly, Involvement of the complement system in the pathogenesis of pulmonary leukostasis in experimental myelocytic leukemia. Leukemia. ,vol. 7, pp. 1608- 1614 ,(1993)
John C. Byrd, Jamie K. Waselenko, Thomas J. Maneatis, Timothy Murphy, Frank T. Ward, Brian P. Monahan, Melissa A. Sipe, Sarah Donegan, Christine A. White, Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance Journal of Clinical Oncology. ,vol. 17, pp. 791- 795 ,(1999) , 10.1200/JCO.1999.17.3.791
C DEFIJTER, J SCHUUR, B POTTERVANLOON, W KINGMA, M SCHWEITZER, Acute cardiorespiratory failure as presenting symptom of chronic lymphocytic leukemia. Netherlands Journal of Medicine. ,vol. 49, pp. 33- 37 ,(1996) , 10.1016/0300-2977(96)00008-3